Calcium Dobesilate vs Flavonoids for the Treatment of Early Hemorrhoidal Disease
Launched by SERVICES HOSPITAL, LAHORE · May 20, 2016
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Grade I and Grade II hemorrhoids
- Exclusion Criteria:
- • CLD
- • colorectal/ anorectal Malignancy
- • self medication
- • local Quack Hakeem medication
- • pregnancy
About Services Hospital, Lahore
Services Hospital, Lahore, is a leading healthcare institution dedicated to advancing medical research and patient care through rigorous clinical trials. Equipped with state-of-the-art facilities and a multidisciplinary team of healthcare professionals, the hospital aims to enhance treatment methodologies and contribute to the global medical community. By collaborating with various stakeholders, Services Hospital fosters an environment of innovation and excellence, ensuring the highest standards of safety and ethical conduct in all clinical studies. Committed to improving health outcomes, the hospital plays a pivotal role in the development of new therapies and interventions that benefit patients both locally and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lahore, Punjab, Pakistan
Patients applied
Trial Officials
Dr. Waris Farooka, MBBS, FCPS, FRCS, FACS
Study Director
Services Institute of Medical Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials